|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10391040104110421043104410451046104710481049...10631064» |
- Oncaspar liquid (pegaspargase) / Servier, Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy: Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 25, 2013
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting
- |||||||||| Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK
New P3 trial: A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 21, 2013
P3, N=707, Completed, Sponsor: GlaxoSmithKline
- fluticasone / Generic mfg.
Trial initiation date: InFLOWt: Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease (clinicaltrials.gov) - Mar 21, 2013
P=N/A, N=58, Recruiting, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Mar 2013
- fluticasone / Generic mfg.
Enrollment open: InFLOWt: Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease (clinicaltrials.gov) - Mar 21, 2013
P=N/A, N=58, Recruiting, Sponsor: Department of Veterans Affairs
Initiation date: Nov 2012 --> Mar 2013 Not yet recruiting --> Recruiting
- |||| abiraterone acetate / Generic mfg.
Trial completion: Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer (clinicaltrials.gov) - Mar 21, 2013
P1/2, N=66, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || hydrocortisone / Generic mfg.
New P2/3 trial: HyStOON: Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock. (clinicaltrials.gov) - Mar 20, 2013
P2/3, N=60, Recruiting, Sponsor: Centre Hospitalier Régional d'Orléans
- ||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion: A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Mar 20, 2013
P3, N=852, Completed, Sponsor: Sunovion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment change: Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP (clinicaltrials.gov) - Mar 20, 2013
P2, N=21, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Active, not recruiting --> Completed N=30 --> 21
- lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Post-transplantation: Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Mar 20, 2013
P2, N=44, Recruiting, Sponsor: University of Chicago
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg.
New P2 trial: Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome (clinicaltrials.gov) - Mar 20, 2013
P2, N=50, Recruiting, Sponsor: Peking Union Medical College Hospital
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP (clinicaltrials.gov) - Mar 20, 2013
P2, N=21, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
N=30 --> 21 Recruiting --> Completed
- sirolimus / Generic mfg., pemetrexed / Generic mfg.
Trial completion: Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 20, 2013
P2, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | perifosine (D21266) / AEterna Zentaris
Trial termination: Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients (clinicaltrials.gov) - Mar 19, 2013
P3, N=135, Terminated, Sponsor: AEterna Zentaris
Active, not recruiting --> Completed Recruiting --> Terminated
- | dexamethasone / Generic mfg.
Enrollment change: Exercise Versus Corticosteroid Randomized Clinical Trial for Plantar Fasciitis (clinicaltrials.gov) - Mar 19, 2013
P2/3, N=56, Completed, Sponsor: University of British Columbia
Recruiting --> Terminated N=100 --> 56
- | perifosine (D21266) / AEterna Zentaris
Enrollment change: Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients (clinicaltrials.gov) - Mar 19, 2013
P3, N=135, Terminated, Sponsor: AEterna Zentaris
N=100 --> 56 N=450 --> 135
- | dexamethasone / Generic mfg.
Trial completion: Exercise Versus Corticosteroid Randomized Clinical Trial for Plantar Fasciitis (clinicaltrials.gov) - Mar 19, 2013
P2/3, N=56, Completed, Sponsor: University of British Columbia
N=450 --> 135 Recruiting --> Completed
- | budesonide inhalation suspension / Generic mfg.
New P2 trial, Surgery: Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery (clinicaltrials.gov) - Mar 18, 2013
P2, N=70, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- Sylvant (siltuximab) / Jazz
Trial termination, Combination therapy: A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 18, 2013
P1, N=9, Terminated, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed Active, not recruiting --> Terminated; Protocol was stopped due to the safety issue in Global
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 18, 2013
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Terminated; Protocol was stopped due to the safety issue in Global Suspended --> Recruiting
- bortezomib / Generic mfg., pomalidomide / Generic mfg.
Clinical: First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD (clinicaltrials.gov) - Mar 17, 2013
P1, N=36, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Suspended --> Recruiting Initiation date: Nov 2012 --> Mar 2013
- pegylated liposomal doxorubicin / Generic mfg., carfilzomib / Generic mfg.
Clinical: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 17, 2013
P1/2, N=53, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Nov 2012 --> Mar 2013 Initiation date: Jun 2011 --> May 2012
- bortezomib / Generic mfg., pomalidomide / Generic mfg.
Clinical: First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD (clinicaltrials.gov) - Mar 17, 2013
P1, N=36, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Initiation date: Jun 2011 --> May 2012 Not yet recruiting --> Recruiting
- |||||| Ninlaro (ixazomib) / Takeda
Enrollment open: TOURMALINE-MM1: A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 17, 2013
P3, N=703, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Ongoing --> Recruiting
- Decadron (dexamethasone) / Merck (MSD), Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=20, Recruiting, Sponsor: Washington University School of Medicine
Ongoing --> Recruiting Suspended --> Recruiting
- | abiraterone acetate / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Metastases: A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel (clinicaltrials.gov) - Mar 14, 2013
P2, N=47, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Suspended --> Recruiting N=38 --> 47
- ||||| carfilzomib / Generic mfg.
P2 data: A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 (clinicaltrials.gov) - Mar 14, 2013
P2, N=55, Recruiting, Sponsor: Hackensack University Medical Center
- | carfilzomib / Generic mfg.
Clinical: CARAMEL 2: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (clinicaltrials.gov) - Mar 14, 2013
P2, N=43, Recruiting, Sponsor: Mayo Clinic
- | abiraterone acetate / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Metastases: A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel (clinicaltrials.gov) - Mar 14, 2013
P2, N=47, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=38 --> 47 Recruiting --> Active, not recruiting
- ||||||| Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Trial completion: A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604) (clinicaltrials.gov) - Mar 13, 2013
P3, N=748, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | dexamethasone injection / Generic mfg.
New P4 trial: Dexamethasone for Post-cesarean Delivery Pain (clinicaltrials.gov) - Mar 13, 2013
P4, N=104, Recruiting, Sponsor: Duke University
- || Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Enrollment closed: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 13, 2013
P=N/A, N=166, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- || dexamethasone / Generic mfg., pregabalin / Generic mfg.
New P3 trial, Surgery: DEXA-PG-HD: Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery (clinicaltrials.gov) - Mar 12, 2013
P3, N=160, Not yet recruiting, Sponsor: University Hospital, Clermont-Ferrand
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open: A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL (clinicaltrials.gov) - Mar 11, 2013
P1/2, N=16, Recruiting, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
Suspended --> Active, not recruiting Suspended --> Recruiting
- | Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Enrollment change: Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma (clinicaltrials.gov) - Mar 10, 2013
P2, N=31, Completed, Sponsor: Novartis
Suspended --> Recruiting N=24 --> 31
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Trial termination: Initial Treatment of Patients With Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Mar 10, 2013
P3, N=8, Terminated, Sponsor: New England Research Institutes
N=24 --> 31 Recruiting --> Terminated; The study was closed due to accrual futility there were only a total of 8 subjects enrolled.
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Enrollment change: Initial Treatment of Patients With Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Mar 10, 2013
P3, N=8, Terminated, Sponsor: New England Research Institutes
Recruiting --> Terminated; The study was closed due to accrual futility there were only a total of 8 subjects enrolled. N=140 --> 8
- || Kineret (anakinra) / SOBI
Clinical: Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis (clinicaltrials.gov) - Mar 10, 2013
P2/3, N=130, Not yet recruiting, Sponsor: Mack Mitchell
- bortezomib / Generic mfg.
Enrollment open, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 10, 2013
P2, N=17, Recruiting, Sponsor: Stanford University
N=140 --> 8 Not yet recruiting --> Recruiting
- | Veramyst (fluticasone furoate nasal spray) / GSK
New P2 trial: To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma (clinicaltrials.gov) - Mar 7, 2013
P2, N=28, Completed, Sponsor: GlaxoSmithKline
- ||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Trial completion: Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma (clinicaltrials.gov) - Mar 7, 2013
P3, N=351, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Combination therapy: MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 7, 2013
P1/2, N=259, Active, not recruiting, Sponsor: Celgene Corporation
Recruiting --> Completed N=30 --> 259
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 7, 2013
P1/2, N=26, Recruiting, Sponsor: AIDS Malignancy Clinical Trials Consortium
N=30 --> 259 N=18 --> 26
- dexamethasone / Generic mfg.
New P2 trial: Facet Versus Trigger Point Injections for Chronic Neck Pain (clinicaltrials.gov) - Mar 7, 2013
P2, N=43, Not yet recruiting, Sponsor: Lawson Health Research Institute
- ||||| melphalan / Generic mfg., pomalidomide / Generic mfg.
Clinical: Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis (clinicaltrials.gov) - Mar 6, 2013
P1/2, N=54, Recruiting, Sponsor: M.D. Anderson Cancer Center
- everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Enrollment open, Biopsy: Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium (clinicaltrials.gov) - Mar 5, 2013
P3, N=50, Recruiting, Sponsor: University of Miami
N=18 --> 26 Not yet recruiting --> Recruiting
- |||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Trial completion: LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - Mar 5, 2013
P2, N=376, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Ninlaro (ixazomib) / Takeda
Enrollment change: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib (clinicaltrials.gov) - Mar 3, 2013
P2, N=103, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed N=33 --> 103
- ||||||| betamethasone / Generic mfg., gentamicin sulfate / Generic mfg.
Trial completion: Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous (clinicaltrials.gov) - Feb 28, 2013
P3, N=76, Completed, Sponsor: EMS
N=33 --> 103 Not yet recruiting --> Completed
- | Tavegil (clemastine) / GSK
Trial initiation date, Head-to-Head: Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment (clinicaltrials.gov) - Feb 28, 2013
P3, N=30, Recruiting, Sponsor: EMS
Not yet recruiting --> Completed Initiation date: Mar 2011 --> Sep 2012
- ARC 100 / Cortice Biosci
Enrollment change, Metastases: TPI 287 in Breast Cancer Metastatic to the Brain (clinicaltrials.gov) - Feb 28, 2013
P2, N=69, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Mar 2011 --> Sep 2012 N=51 --> 69